Axelyf discloses equity financing with founder debt conversions
The reported securities total includes approximately $800,000 in conversions, leaving the exact new cash amount unspecified.
Axelyf reported $2,631,439 in securities sold to eight investors in a Form D filed on October 13, 2026. The notice explicitly includes approximately $800,000 of founder related debt and note conversions in that total.
The exact new cash amount is therefore unspecified. The offering began on October 7 and had $68,561 remaining against a $2.7 million target. The notice does not identify the subscribers or a named venture stage.
This is a new offering with a different first sale date from the company’s 2025 financing. Axelyf develops RNA medicines using its AXL lipid nanoparticle delivery platform, with programs for solid tumors and autoimmune disease.